JP2021528399A5 - - Google Patents
Info
- Publication number
- JP2021528399A5 JP2021528399A5 JP2020570143A JP2020570143A JP2021528399A5 JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5 JP 2020570143 A JP2020570143 A JP 2020570143A JP 2020570143 A JP2020570143 A JP 2020570143A JP 2021528399 A5 JP2021528399 A5 JP 2021528399A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- formulation
- binds
- formulation according
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688476P | 2018-06-22 | 2018-06-22 | |
| US62/688,476 | 2018-06-22 | ||
| US201962855205P | 2019-05-31 | 2019-05-31 | |
| US62/855,205 | 2019-05-31 | ||
| PCT/US2019/038600 WO2019246595A1 (en) | 2018-06-22 | 2019-06-21 | Dosing regimens for targeted tgf-b inhibition for use in treating biliary tract cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021528399A JP2021528399A (ja) | 2021-10-21 |
| JP2021528399A5 true JP2021528399A5 (https=) | 2022-09-12 |
Family
ID=68982740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570143A Pending JP2021528399A (ja) | 2018-06-22 | 2019-06-21 | 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210214446A1 (https=) |
| EP (1) | EP3810654A4 (https=) |
| JP (1) | JP2021528399A (https=) |
| KR (1) | KR20210022680A (https=) |
| CN (1) | CN112673020A (https=) |
| AU (1) | AU2019288765A1 (https=) |
| BR (1) | BR112020026159A2 (https=) |
| CA (1) | CA3103908A1 (https=) |
| CL (1) | CL2020003323A1 (https=) |
| IL (1) | IL279647A (https=) |
| MX (1) | MX2020014166A (https=) |
| SG (1) | SG11202012688UA (https=) |
| TW (1) | TW202019959A (https=) |
| WO (1) | WO2019246595A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202304979A (zh) * | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| WO2023045141A1 (zh) * | 2021-09-26 | 2023-03-30 | 上海迈泰君奥生物技术有限公司 | 一种双功能融合蛋白 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
| WO2018129331A1 (en) * | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
-
2019
- 2019-06-21 KR KR1020217001689A patent/KR20210022680A/ko not_active Withdrawn
- 2019-06-21 AU AU2019288765A patent/AU2019288765A1/en not_active Abandoned
- 2019-06-21 WO PCT/US2019/038600 patent/WO2019246595A1/en not_active Ceased
- 2019-06-21 TW TW108121691A patent/TW202019959A/zh unknown
- 2019-06-21 CA CA3103908A patent/CA3103908A1/en active Pending
- 2019-06-21 SG SG11202012688UA patent/SG11202012688UA/en unknown
- 2019-06-21 CN CN201980054914.7A patent/CN112673020A/zh active Pending
- 2019-06-21 JP JP2020570143A patent/JP2021528399A/ja active Pending
- 2019-06-21 EP EP19822318.2A patent/EP3810654A4/en not_active Withdrawn
- 2019-06-21 BR BR112020026159-9A patent/BR112020026159A2/pt not_active Application Discontinuation
- 2019-06-21 MX MX2020014166A patent/MX2020014166A/es unknown
-
2020
- 2020-12-17 US US17/125,108 patent/US20210214446A1/en not_active Abandoned
- 2020-12-21 IL IL279647A patent/IL279647A/en unknown
- 2020-12-21 CL CL2020003323A patent/CL2020003323A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106604750B (zh) | 治疗骨髓瘤 | |
| JP2019517549A5 (https=) | ||
| JP2016530280A5 (https=) | ||
| TW201922793A (zh) | Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途 | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2012067116A5 (https=) | ||
| WO2013152034A1 (en) | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
| JP2020510039A5 (https=) | ||
| JP2015517529A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2015525798A5 (https=) | ||
| TW201922282A (zh) | Ｐｄ-１抗體和表觀遺傳調節劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2021527083A5 (https=) | ||
| JP2019521156A5 (https=) | ||
| JP2018512402A5 (https=) | ||
| CN101657215A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| TW202330040A (zh) | 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2020517671A5 (https=) | ||
| JP2025508786A5 (https=) | ||
| JP2021523096A5 (https=) | ||
| JP2009544610A5 (https=) | ||
| JP2021528399A5 (https=) | ||
| JP2021529777A5 (https=) | ||
| JP2023546503A5 (https=) | ||
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 |